Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsConnectiCare Emflaza Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentConnectiCarePolicy C10904-A

    Emflaza (deflazacort) Coverage Criteria

    Customize your policy alerts

    Sign up for ConnectiCare Policy C10904-A alerts

    Get alerted when Policy C10904-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage determinations for oral deflazacort products, including Emflaza, Jaythari, Kymbee, and Pyqui, primarily for Duchenne muscular dystrophy; the policy considers deflazacort not medically necessary for all indications.

    Policy Summary
    PayerConnectiCare
    PolicyEmflaza (deflazacort) Coverage Criteria
    Policy CodePolicy C10904-A
    Change TypeNo material change
    Effective DateMay 30, 2026
    Next Review DateOctober 1, 2026
    Key ActionSubmit complete medical rationale and supporting patient records, test results, and provider credentials when requested.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not coveredCoverage stance
    DMDPolicy diagnosis
    PrednisonePreferred corticosteroid
    DMD onlySupported indication
    Oral

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Route

    Coverage Criteria

    Deflazacort not medically necessary

    Deflazacort is considered not medically necessary for all indications, including Duchenne muscular dystrophy.

    Not medically necessary

    • Deflazacort is considered not medically necessary for all indications, including Duchenne muscular dystrophy, because published evidence is limited and does not establish clinical effectiveness or superiority over standard generic prednisone or other oral corticosteroids, such as methylprednisolone and prednisolone.

      Long-term benefits and risks compared with prednisone are not adequately supported. Prednisone is the preferred agent for DMD.

    Off-label uses

    Off-label uses are not authorized.

    Off-label exclusion

    • Deflazacort will not be authorized for off-label uses because its application in other disease states has not been evaluated by the FDA.

      FDA-approved indication alone does not dictate coverage.

    Off-label uses of deflazacort are excluded from authorization because the drug has not been evaluated by the FDA for other disease states. Access obtained through importation from outside the United States does not qualify as therapy or continuation of treatment. Pharmaceutical samples from a prescriber or manufacturer assistance program are not considered when evaluating the medical condition, prior prescription history, or continuation of therapy.

    Do not use Emflaza (deflazacort) in patients with known hypersensitivity to deflazacort or any inactive ingredient. Use is also excluded with strong or moderate CYP3A4 inducers, including efavirenz, carbamazepine, or phenytoin. Live or live attenuated vaccines should not be administered.

    Deflazacort is considered not medically necessary for all indications, including the FDA-approved treatment of Duchenne muscular dystrophy. The policy cites insufficient evidence to establish clinical effectiveness or superiority over standard generic prednisone or other oral corticosteroids, along with inadequate long-term benefit-risk data. FDA approval alone does not dictate coverage.

    Provider Actions and Denial Considerations

    Documentation Required

    Medical Rationale and Records

    When requesting an exception to these guidelines, the provider must submit complete medical rationale. The plan may require additional documentation for coverage determination, quality improvement, and fraud, waste, and abuse prevention.

    • Provide patient records and relevant test results.
    • Include the credentials of the provider ordering or performing the drug or service.
    Denial Risk

    Deflazacort Not Medically Necessary

    Emflaza (deflazacort) is considered not medically necessary for all indications, including Duchenne muscular dystrophy (DMD), because evidence is insufficient to establish clinical effectiveness or superiority over standard generic prednisone and long-term benefits and risks are not adequately established.

    Clinical Background

    Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder involving the absence or near-absence of dystrophin in muscle cells. Dystrophin deficiency causes progressive muscle damage and loss of physical function, which may eventually lead to respiratory or cardiac failure. Treatment focuses on symptom management and slowing disease progression; glucocorticoids may help prolong ambulation, improve pulmonary function, delay cardiomyopathy, and reduce scoliosis.

    Definitions

    Duchenne muscular dystrophy (DMD)
    ConditionDuchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder.
    Underlying defectThe disorder results from the absence or near-absence of dystrophin protein in muscle cells.
    ProgressionIt causes muscle damage, progressive loss of physical function, and ultimately premature death from respiratory and/or cardiac failure.
    Duchenne muscular dystrophy (DMD)
    ConditionDuchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder.
    DystrophinDMD is characterized by the absence or near-absence of dystrophin in muscle cells.
    Policy Summary
    PayerConnectiCare
    PolicyEmflaza (deflazacort) Coverage Criteria
    Policy CodePolicy C10904-A
    Change TypeNo material change
    Effective DateMay 30, 2026
    Next Review DateOctober 1, 2026
    Key ActionSubmit complete medical rationale and supporting patient records, test results, and provider credentials when requested.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Denial ConsiderationsClinical BackgroundDefinitions
  1. Prednisone is the preferred DMD agent because it has been the mainstay of therapy and is more cost-effective.
  2. The FDA-approved indication does not, by itself, establish coverage; review the policy in its entirety.
    3. Denial Risk

    Off-Label Uses Not Authorized

    Deflazacort will not be authorized for off-label uses because its application in other disease states has not been evaluated by the FDA.

    Denial Risk

    Imported Products and Samples Excluded

    Products obtained through importation from outside the United States are not qualifying factors for therapy or continuation of treatment. Pharmaceutical samples, including samples from a prescriber or manufacturer assistance program, will not be considered when evaluating the medical condition, prior prescription history, or continuation of therapy.

    • Do not rely on imported products or pharmaceutical samples to establish eligibility for treatment or continuation.
    Denial Risk

    Insufficient Supporting Documentation

    The plan may deny reimbursement or take other appropriate action when submitted documentation does not support that the drug or service is medically necessary, non-investigational, non-experimental, and within the member’s benefits. Action may also be taken when documentation demonstrates inappropriate or excessive billing or other practice.

    • Ensure supporting records substantiate medical necessity and the non-investigational, non-experimental status of the requested therapy.
    Denial Risk

    Contraindications and Exclusions

    Coverage or use is excluded for patients with known hypersensitivity to deflazacort or any inactive ingredient, and for co-administration with strong or moderate CYP3A4 inducers. Live or live-attenuated vaccines should not be administered with Emflaza.

    • Strong CYP3A4 inducer example: efavirenz.
    • Moderate CYP3A4 inducer examples: carbamazepine and phenytoin.
    • Do not administer live or live-attenuated vaccines.
    Functional impact
    The condition results in progressive muscle damage and loss of physical function.
    Deflazacort
    Drug classDeflazacort is a glucocorticoid prodrug and a methyloxazolone derivative of prednisolone.
    Active metaboliteIts active metabolite has anti-inflammatory and immunosuppressant properties.
    Dose equivalenceApproximately 1.2 mg of deflazacort is equivalent to 1 mg of prednisone.
    Level A
    ClassificationLevel A means the treatment, test, or predictor is established as effective, ineffective, harmful, useful, predictive, or not useful or predictive for the given condition in the specified population.
    Evidence requirementA Level A rating generally requires at least two consistent Class I studies.
    ExceptionIn exceptional cases, one convincing Class I study may suffice when all criteria are met, the relative rate of improved outcome exceeds 5, and the lower confidence limit exceeds 2.
    Level B
    ClassificationLevel B means the treatment, test, or predictor is probably effective, ineffective, harmful, useful, predictive, or not useful or predictive for the given condition in the specified population.
    Evidence requirementA Level B rating requires at least one Class I study or two consistent Class II studies.
    ScopeThe classification may describe probable benefit, lack of benefit, harm, usefulness, predictive value, or lack of usefulness or predictive value.
    Level C
    ClassificationLevel C means the treatment, test, or predictor is possibly effective, ineffective, harmful, useful, predictive, or not useful or predictive for the given condition in the specified population.
    Evidence requirementA Level C rating requires at least one Class II study or two consistent Class III studies.
    ScopeThe classification may describe possible benefit, lack of benefit, harm, usefulness, predictive value, or lack of usefulness or predictive value.
    Level U
    ClassificationLevel U means the available data are inadequate or conflicting.
    Evidence conclusionBased on current knowledge, the treatment, test, or predictor is unproven.
    InterpretationA Level U classification indicates that the available evidence does not support or refute the specified treatment, test, or predictor.